Logotype for InnovAge Holding Corp

InnovAge (INNV) Q1 2025 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for InnovAge Holding Corp

Q1 2025 earnings summary

8 Jul, 2026

Executive summary

  • First quarter fiscal 2025 revenues reached $205.1 million, up 12.4% year-over-year, with Adjusted EBITDA of $6.5 million, a 500% increase year-over-year and margin improving to 3.2%.

  • Net loss narrowed to $5.7 million from $11 million year-over-year, with net loss margin improving to 2.8% from 6.0%.

  • Participant census increased to approximately 7,210, up 10% year-over-year, reflecting improved sales, marketing, and operational execution.

  • Leadership transition included the appointment of a new President and COO, Michael Scarbrough, bringing extensive healthcare experience.

  • Served approximately 7,210 PACE participants across 20 centers in six states as of September 30, 2024, maintaining status as the largest PACE provider in the U.S.

Financial highlights

  • Total revenues were $205.1 million, up 12.4% year-over-year, driven by higher member months and increased capitation rates.

  • Center-level contribution margin increased to $34.5 million (16.8% of revenue), up from $27.9 million (15.3%).

  • Net loss narrowed to $5.7 million from $11 million year-over-year; Adjusted EBITDA margin improved to 3.2% from 0.7%.

  • Ended the quarter with $39 million in cash, $46.7 million in short-term investments, and $81.3 million in total debt.

  • Operating loss improved to $4.9 million from $10.7 million year-over-year.

Outlook and guidance

  • Fiscal 2025 guidance: revenue between $815 million and $865 million; Adjusted EBITDA between $24 million and $31 million.

  • Participant census expected between 7,300 and 7,750; total member months between 86,000 and 89,000.

  • De novo losses for fiscal 2025 expected in the $18–$20 million range.

  • Growth expected to be linear with some seasonal slowdown in Q3; financial impact of member month growth weighted toward the back half of the year.

  • Expect continued elevated operating expenses in fiscal 2025 due to census growth and labor costs, but anticipate clinical and operational initiatives will help offset cost pressures.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more